Combination therapy for chronic hepatitis C;Kombinationstherapie der chronischen virushepatitis C

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 8, 2003, Pages 370-374

  Zeuzem, Stefan ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; MACROGOL; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; DEATH; HEMODIALYSIS; HEPATITIS C; HUMAN; REVIEW; VIRUS REPLICATION;

AMANTADINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 0037459018     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37369     Document Type: Review

References (17)

1. Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Spengler U, Goeser T, Pape G, Hopf U, Zeuzem S. Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: results of a double-blind, placebo-controlled trial. J Hepatol 2002; 36 (Suppl); 3
2. Fried MW, Shiffman ML, Reddy RK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002; 347: 975-982
3. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556-567
4. Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Jr. Sette H, Ramadori G, Bodenheimer HC, Marcellin P, Lee S-D, Roberts PJ, Ackrill AM. Peginterferon alfa-2a (40KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36 (Suppl 1); 3
5. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antivir Ther 2000; 5: 85-90
6. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65
8. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492
9. Niederau C. Therapie der chronischen Hepatitis C mit pegylierten Alpha-Interferonen. Dtsch Med Wochenschr 2002; 127: 563-566
10. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432
11. Reddy KR, Wright TL, Pockros PJ et al. Efficacy and safety of pegylated (40 kd) interferon alfa-2a compared with interferon alfa-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438
12. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116: 378-386
13. Xu ZX, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetics/ pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated interferon (PEG-IFN) and interferon alfa-2a (IFN alfa-2a) to healthy subjects. Hepatology 1998; 28 (Suppl); 702
14. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999; 131: 174-181
15. Wedemeyer H, Cornberg M, Manns MP. PEG-Interferone: Bedeutung für die Therapie der Virushepatitis B und C. Dtsch Med Wochenschr 2001; S126: 68-75
16. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672
17. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 1438-1447